The stock is trading at $5.47 which is quite a bit higher than the 50 day moving average which is $4.91 and a great deal higher than the 200 day moving average of $3.68. The 50 day moving average was up by +11.48% and the 200 day average went up $1.79 or +48.64%. 2,619 shares changed hands on Tuesday. Overall, volume was down 95.55% under the stocks normal daily volume.
Investors are a little more bearish on the company as evidenced by the motion in short interest. The firm saw a rise in short interest of 3.15% as of the latest report on September 29, 2017. Short shares increased 12,835 over that timeframe. Days to cover decreased -4.0 to 1.0 and the percentage of shorted shares was 0.02% on September 29.
These firms have modified their investment in DRNA. As of the end of the quarter Quotient Investors, LLC had bought 5,700 shares growing its holdings by 41.9%. The value in dollars went from $46,000 to $61,000 a change of $15,000 quarter to quarter. As of quarter end Sabby Management, LLC had disposed of a total of 10,000 shares trimming its stake by 5.0%. The value of the investment in (DRNA) decreased from $680,000 to $602,000 a change of 11.5% since the last quarter.
As of the end of the quarter Ecor1 Capital, LLC had bought a total of 385,992 shares growing its position 101.0%. The value of the investment in DRNA increased from $1,299,000 to $2,435,000 increasing 87.5% for the reporting period. As of the end of the quarter Ubs Group Ag had sold a total of 712 shares trimming its stake by 0.3%. The value of the investment in Dicerna Pharmaceuticals, Inc. went from $968,000 to $900,000 a change of 7.0% quarter over quarter.
As of the last earnings report the EPS was $-3.20 and is projected to be $-2.70 for the current year with 20,844,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.69 and the next full year EPS is projected to be $-2.76.
Dicerna Pharmaceuticals, Inc., launched on October 24, 2006, is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas..